Jerome A Schofferman, MD | |
1850 Sullivan Ave, Suite 200, Daly City, CA 94015-2221 | |
(650) 985-7500 | |
(650) 985-7511 |
Full Name | Jerome A Schofferman |
---|---|
Gender | Male |
Speciality | Pain Medicine - Pain Medicine |
Location | 1850 Sullivan Ave, Daly City, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1477525509 | NPI | - | NPPES |
P00066665 | Other | CA | MEDICARE RAILORAD PIN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208VP0000X | Pain Medicine - Pain Medicine | G21414 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jerome A Schofferman, MD 1850 Sullivan Ave, Suite 200, Daly City, CA 94015-2221 Ph: (650) 985-7500 | Jerome A Schofferman, MD 1850 Sullivan Ave, Suite 200, Daly City, CA 94015-2221 Ph: (650) 985-7500 |
News Archive
Using a unique data set spanning 40 years of dengue fever incidence in Thailand, an international team led by biostatistician Nicholas Reich at the University of Massachusetts Amherst has for the first time estimated from data that after an initial dengue infection, a person is protected from infection with other strains for between one and three years.
Statins, a class of cholesterol-lowering drugs found in millions of medicine cabinets, may help treat Rett Syndrome, according to a study published today in Nature Genetics. The Rett Syndrome Research Trust (RSRT) funded this work with generous support from the Rett Syndrome Research Trust UK and Rett Syndrome Research & Treatment Foundation.
Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc., announces that it has entered the rapidly growing Epigenetics field, with the launch of the first kits in the new EPIK™ product range; EPIK™ Fast Quantification Kit and EPIK™ Amplification Kit.
› Verified 3 days ago